PMID- 29512935
OWN - NLM
STAT- MEDLINE
DCOM- 20181121
LR  - 20190610
IS  - 1399-3062 (Electronic)
IS  - 1398-2273 (Print)
IS  - 1398-2273 (Linking)
VI  - 20
IP  - 3
DP  - 2018 Jun
TI  - Cytomegalovirus infections in lung and hematopoietic cell transplant recipients 
      in the Organ Transplant Infection Prevention and Detection Study: A multi-year, 
      multicenter prospective cohort study.
PG  - e12877
LID - 10.1111/tid.12877 [doi]
AB  - BACKGROUND: Most studies of post-transplant CMV infection have focused on either 
      solid organ or hematopoietic cell transplant (HCT) recipients. A large 
      prospective cohort study involving both lung and HCT recipients provided an 
      opportunity to compare the epidemiology and outcomes of CMV infections in these 2 
      groups. METHODS: Patients were followed up for 30 months in a 6-center 
      prospective cohort study. Data on demographics, CMV infections, tissue-invasive 
      disease, recurrences, rejection, and immunosuppression were recorded. RESULTS: 
      The overall incidence of CMV infection was 83/293 (28.3%) in the lung transplant 
      group and 154/444 (34.7%) in the HCT group (P = .0706). Tissue-invasive CMV 
      disease occurred in 8/83 (9.6%) of lung and 6/154 (3.9%) of HCT recipients with 
      CMV infection, respectively (P = .087). Median time to CMV infection was longer 
      in the lung transplant group (236 vs 40 days, P < .0001), likely reflecting the 
      effects of prophylaxis vs preemptive therapy. Total IgG levels of < 350 mg/dL in 
      lung recipients and graft vs host disease (GvHD) in HCT recipients were 
      associated with increased CMV risk. HCT recipients had a higher mean number of 
      CMV episodes (P = .008), although duration of viremia was not significantly 
      different between the 2 groups. CMV infection was not associated with reduced 
      overall survival in either group. CONCLUSIONS: Current CMV prevention strategies 
      have resulted in a low incidence of tissue-invasive disease in both lung 
      transplant and HCT, although CMV viremia is still relatively common. Differences 
      between the lung and HCT groups in terms of time to CMV and recurrences of CMV 
      viremia likely reflect differences in underlying host immunobiology and in CMV 
      prevention strategies in the modern era.
CI  - (c) 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Avery, Robin K
AU  - Avery RK
AUID- ORCID: 0000-0001-7692-3619
AD  - Division of Infectious Diseases, Johns Hopkins University, Baltimore, MD, USA.
FAU - Silveira, Fernanda P
AU  - Silveira FP
AD  - University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
FAU - Benedict, Kaitlin
AU  - Benedict K
AD  - Centers for Disease Control and Prevention, Atlanta, GA, USA.
FAU - Cleveland, Angela A
AU  - Cleveland AA
AD  - Centers for Disease Control and Prevention, Atlanta, GA, USA.
FAU - Kauffman, Carol A
AU  - Kauffman CA
AD  - University of Michigan Medical School and Veterans Affairs Ann Arbor Healthcare 
      System, Ann Arbor, MI, USA.
FAU - Schuster, Mindy G
AU  - Schuster MG
AD  - University of Pennsylvania, Philadelphia, PA, USA.
FAU - Dubberke, Erik R
AU  - Dubberke ER
AUID- ORCID: 0000-0003-3779-2796
AD  - Washington University School of Medicine, St. Louis, MO, USA.
FAU - Husain, Shahid
AU  - Husain S
AD  - University of Toronto Medical Center, Toronto, ON, Canada.
FAU - Paterson, David L
AU  - Paterson DL
AD  - University of Queensland, Brisbane, QLD, Australia.
FAU - Chiller, Tom
AU  - Chiller T
AD  - Centers for Disease Control and Prevention, Atlanta, GA, USA.
FAU - Pappas, Peter
AU  - Pappas P
AD  - University of Alabama at Birmingham, Birmingham, AL, USA.
LA  - eng
GR  - CC999999/Intramural CDC HHS/United States
PT  - Journal Article
PT  - Multicenter Study
DEP - 20180330
PL  - Denmark
TA  - Transpl Infect Dis
JT  - Transplant infectious disease : an official journal of the Transplantation 
      Society
JID - 100883688
RN  - 0 (Antiviral Agents)
RN  - P9G3CKZ4P5 (Ganciclovir)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antiviral Agents/administration & dosage
MH  - Cytomegalovirus/drug effects/immunology/isolation & purification
MH  - Cytomegalovirus Infections/*epidemiology/immunology/mortality/*prevention & 
      control
MH  - Female
MH  - Ganciclovir/administration & dosage
MH  - Graft vs Host Disease/epidemiology
MH  - Hematopoietic Stem Cell Transplantation/*adverse effects/statistics & numerical 
      data
MH  - Humans
MH  - Incidence
MH  - Lung Transplantation/*adverse effects/statistics & numerical data
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Transplant Recipients/*statistics & numerical data
MH  - Viremia/epidemiology/prevention & control
PMC - PMC5989001
MID - NIHMS971270
OTO - NOTNLM
OT  - cytomegalovirus
OT  - lung transplant
OT  - multicenter cohort study
OT  - stem cell transplant
EDAT- 2018/03/08 06:00
MHDA- 2018/11/22 06:00
PMCR- 2019/06/01
CRDT- 2018/03/08 06:00
PHST- 2017/07/16 00:00 [received]
PHST- 2017/11/27 00:00 [revised]
PHST- 2017/12/24 00:00 [accepted]
PHST- 2018/03/08 06:00 [pubmed]
PHST- 2018/11/22 06:00 [medline]
PHST- 2018/03/08 06:00 [entrez]
PHST- 2019/06/01 00:00 [pmc-release]
AID - 10.1111/tid.12877 [doi]
PST - ppublish
SO  - Transpl Infect Dis. 2018 Jun;20(3):e12877. doi: 10.1111/tid.12877. Epub 2018 Mar 
      30.